Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines

Venous thromboembolism (VTE) is an important cause of avoidable morbidity and mortality. However, routine prophylaxis for at-risk patients is underused. Recent guidelines issued by an international consensus group, including the International Union of Angiology (IUA), recommend use of low-molecular-...

Descripción completa

Detalles Bibliográficos
Autor principal: Prandoni, Paolo
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546366/
https://www.ncbi.nlm.nih.gov/pubmed/18782432
http://dx.doi.org/10.1186/1477-9560-6-13
_version_ 1782159184098230272
author Prandoni, Paolo
author_facet Prandoni, Paolo
author_sort Prandoni, Paolo
collection PubMed
description Venous thromboembolism (VTE) is an important cause of avoidable morbidity and mortality. However, routine prophylaxis for at-risk patients is underused. Recent guidelines issued by an international consensus group, including the International Union of Angiology (IUA), recommend use of low-molecular-weight heparins (LMWHs) for the treatment of acute VTE and prevention of recurrence, and for prophylaxis in surgical and medical patients. This review highlights current inadequacies in the provision of thromboprophylaxis, and considers the clinical implications of the European guidelines on the prevention and treatment of VTE.
format Text
id pubmed-2546366
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25463662008-09-20 Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines Prandoni, Paolo Thromb J Review Venous thromboembolism (VTE) is an important cause of avoidable morbidity and mortality. However, routine prophylaxis for at-risk patients is underused. Recent guidelines issued by an international consensus group, including the International Union of Angiology (IUA), recommend use of low-molecular-weight heparins (LMWHs) for the treatment of acute VTE and prevention of recurrence, and for prophylaxis in surgical and medical patients. This review highlights current inadequacies in the provision of thromboprophylaxis, and considers the clinical implications of the European guidelines on the prevention and treatment of VTE. BioMed Central 2008-09-09 /pmc/articles/PMC2546366/ /pubmed/18782432 http://dx.doi.org/10.1186/1477-9560-6-13 Text en Copyright © 2008 Prandoni; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Prandoni, Paolo
Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
title Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
title_full Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
title_fullStr Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
title_full_unstemmed Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
title_short Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
title_sort prevention and treatment of venous thromboembolism with low-molecular-weight heparins: clinical implications of the recent european guidelines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546366/
https://www.ncbi.nlm.nih.gov/pubmed/18782432
http://dx.doi.org/10.1186/1477-9560-6-13
work_keys_str_mv AT prandonipaolo preventionandtreatmentofvenousthromboembolismwithlowmolecularweightheparinsclinicalimplicationsoftherecenteuropeanguidelines

Ejemplares similares